✨ Your Portfolio is fetched and updated from zerodha.
Nano Pharmaceuticals

Auro Laboratories Ltd.

AUROLAB

Get real time AI alerts about this company on your WhatsApp!
Market Cap
₹144 Cr.
P/E
135.79

Auro Laboratories Ltd.

  • Auro Laboratories
  • Quest Laboratories
  • Sotac Pharmaceutical

FAQs on Auro Laboratories Ltd. Shareprice

Auro Laboratories has given better returns compared to its competitors.
Auro Laboratories has grown at ~14.62% over the last 1yrs while peers have grown at a median rate of -18.0%

Yes, Auro Laboratories is expensive.
Latest PE of Auro Laboratories is 135, while 3 year average PE is 34.28.
Also latest EV/EBITDA of Auro Laboratories is 51.35 while 3yr average is 21.12.

View FAQ's On Business

Growth Table

  • Auro Laboratories Ltd.
  • Quest Laboratories
  • Sotac Pharmaceutical

Balance Sheet

  • Auro Laboratories Ltd.
  • Quest Laboratories
  • Sotac Pharmaceutical

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end

Profit & Loss

  • Auro Laboratories Ltd.
  • Quest Laboratories
  • Sotac Pharmaceutical

Cash Flow

  • Auro Laboratories Ltd.
  • Quest Laboratories
  • Sotac Pharmaceutical

Cash Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.

Ratios

= Dominant Factor
  • Auro Laboratories Ltd.
  • Quest Laboratories
  • Sotac Pharmaceutical

Quarterly Results

  • Auro Laboratories Ltd.
  • Quest Laboratories
  • Sotac Pharmaceutical

Reverse DCF

locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF

FAQs on Auro Laboratories Ltd. Financials

Balance sheet of Auro Laboratories is moderately strong, But short term working capital might become an issue for this company.

The net debt of Auro Laboratories is decreasing.
Latest net debt of Auro Laboratories is ₹43.28 Crs as of Sep-25.
This is less than Mar-25 when it was ₹43.76 Crs.

No, profit is decreasing.
The profit of Auro Laboratories is ₹1.06 Crs for TTM, ₹1.84 Crs for Mar 2025 and ₹7.79 Crs for Mar 2024.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Auro Laboratories latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%

Companies resources are allocated to majorly unproductive assets like Capital Work in Progress

View FAQ's On Shareholding
Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech